Custom 3D-Printed Immobilization Devices for Precision Care

Custom 3D-Printed Immobilization Devices for Precision Care

MedTech Outlook | Monday, June 22, 2026

For executives evaluating patient-specific immobilization devices, the question is no longer limited to whether 3D printing can produce a better fit. The harder test is whether the device can enter a busy clinical environment without slowing treatment, adding avoidable technology burden or creating uncertainty around reimbursement. In radiation oncology, where planning systems, imaging platforms, records and verification tools already demand disciplined coordination, a new device must reduce friction rather than introduce another dependency.

Manual processes can require repeat visits, technician adjustment and a timeline that does not match the urgency of cancer treatment. A custom device has limited enterprise value if it arrives after simulation planning has moved forward or if its fit varies from case to case. The stronger model compresses design, production and delivery into the treatment window while preserving repeat positioning across the course of therapy. It must reduce variability between sites, so the same standard can be applied whether a hospital treats a small number of eligible patients or manages a larger radiotherapy program.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

“For buyers prioritizing rapid adoption without heavy IT work, Kallisio presents a focused, credible recommendation.”

In addition, procurement teams must be cautious of solutions that require extensive IT integration, transfer unnecessary patient information or depend on new local infrastructure before use. The practical standard is a secure digital pathway that begins with a common scan, protects patient identity and allows the manufacturer to move from anatomy capture to device production without asking the hospital to rebuild its workflow. That distinction matters because adoption delays often come from governance, privacy review and staff training rather than from the device itself.

Manufacturing scale also deserves scrutiny. A single production site may work for early pilots, but broader use requires validated partners close enough to serve different regions without making shipping time the weak link. Quality should be embedded in the digital chain through controlled design rules, approved materials and validated equipment, not left to final inspection alone. Executives should look for evidence that each device can be reproduced consistently across patients, institutions and geographies while remaining easy for therapists to place, clean and reuse.

The financial pathway cannot be treated as an afterthought. Hospitals need clinical relevance, but they also need coding support, payer logic and documentation that make adoption defensible. A device that improves precision yet creates billing ambiguity will face slow committee review. The gold standard is a patient-specific immobilization solution that aligns clinical utility, privacy protection, manufacturing discipline and reimbursement readiness into one acquisition case. Such a solution gives clinical leaders confidence that patient benefit, staff acceptance and administrative justification can move together.

Kallisio merits close attention for organizations evaluating custom 3D-printed immobilization in head and neck radiotherapy. Its Stentra device is FDA-cleared, patient-specific and designed from intraoral scan data to support tongue and jaw positioning during external beam radiation. The company’s workflow uses a secure portal, unique device identification and no PHI transfer, while its platform moves from scan to device delivery in as little as 72 hours. Stentra is built with biocompatible 3D-printing materials, supported by manufacturing partners such as Ricoh and positioned with CPT reimbursement guidance. For buyers prioritizing rapid adoption without heavy IT work, Kallisio presents a focused, credible recommendation.

More in News

Poor illumination, limited viewing range and inconsistent component quality can turn a routine ear or eye examination into a repeat procedure. For procurement teams, the problem is rarely confined to the device itself. It appears later through inconsistent performance across examination settings and difficulties accommodating different patient groups. A sound purchasing decision must therefore look beyond unit price and assess how reliably a device supports daily examination work. Lighting quality deserves close scrutiny because image clarity depends on more than brightness alone. Otoscopes should provide focused illumination, while ophthalmoscopes need stable light paths across a useful range of apertures and dioptric adjustments. Rechargeable formats add convenience, but practical charging also matters for portable use. Buyers should examine whether brightness can be adjusted, whether the optical design supports clear viewing and whether the device remains consistent across varied lighting conditions. “JEASHIA’s ENT range includes fiber-optic LED otoscopes with 3× magnification, adjustable brightness options and rechargeable handles, along with ophthalmoscopes using coaxial parallel light with multiple apertures and dioptric lenses.” Patient variation creates another test. Pediatric and geriatric examinations may require different ear tip sizes, viewing angles or lens settings. Standard kits with narrow accessory ranges can make examinations more difficult or contribute to repeat procedures. A broader set of compatible accessories matters because it allows one device family to serve more exam settings without creating unnecessary stock complexity. The same principle applies to handle design, magnification and controls. Each feature should make the examination easier to complete, not simply add specifications to a product sheet. Manufacturing control also affects long-term reliability. Devices assembled from parts sourced through several suppliers may show variation in fit, finish or electrical behavior. Those differences can be difficult to identify during procurement because they often emerge only after repeated use. Buyers should look for batch traceability, standardized testing and a clear quality system that governs both components and final inspection. Certification is important, but how consistently those controls are applied across production also matters. Video-enabled ENT devices bring another layer of utility when image capture supports remote review or patient follow-up. Recording and storage functions allow clinicians to capture findings and share them for consultation. Compatibility with common mobile systems, practical charging and language options may also affect adoption across distributed care settings. These features carry value only when image quality is stable and the interface remains simple enough for routine use. JEASHIA brings these requirements together through inhouse development and production of optical assemblies, structural parts and circuit control modules. Its ENT range includes fiber-optic LED otoscopes with 3× magnification, adjustable brightness options and rechargeable handles, along with ophthalmoscopes using coaxial parallel light with multiple apertures and dioptric lenses. Its video otoscopes add image capture, recording storage, mobile-system compatibility and Type-C charging. It also supports OEM and ODM customization under ISO 13485 quality controls, with production and inspection aligned with CE and FDA requirements. For buyers that need consistent device behavior, configurable kits and consolidated sourcing, JEASHIA presents a manufacturing model built around inhouse production, customization and quality controls. ...Read more
A purchasing discussion around sterile packaging rarely ends with the selection of a pouch, tray or barrier material. Medical device manufacturers are placing greater attention on how packaging fits into production schedules, validation work and distribution demands. That shift is changing procurement conversations, particularly for companies launching new devices or expanding manufacturing capacity. Packaging has traditionally been viewed as one step before sterilization and shipment. But buyers now tend to evaluate it as part of the larger manufacturing process.  A package that performs well in laboratory testing may still create delays if sealing equipment requires extensive qualification or if material specifications complicate production changes. The issue becomes more noticeable when device portfolios grow.  Different products often require different packaging formats, creating added work for engineering teams responsible for validation and documentation. Procurement departments are no longer comparing materials on technical performance alone. They are also considering how packaging decisions affect production planning and future product changes. Supplier discussions are becoming more detailed as a result. Manufacturers want clearer information about material consistency, compatibility with sterilization methods and long-term availability. Any uncertainty pertaining to material supply can influence production schedules because packaging validation is not always easy to repeat after a specification change. Smaller manufacturers may feel these pressures more acutely. They often have limited engineering resources available for package testing or process qualification.  Repeating seal validation or transportation studies because of a material substitution can consume crucial time for small manufacturers that would otherwise support product development or regulatory preparation. This changing approach also affects supplier relationships. Buyers progressively value suppliers that can support technical discussions throughout qualification rather than limiting engagement to material delivery. Packaging providers are expected to participate in conversations involving manufacturing engineers, quality teams and purchasing staff, even when no immediate product redesign is planned. Distribution expectations additionally complicate procurement decisions. Devices may travel through different climates or storage environments before reaching healthcare facilities.  That is why packaging choices are now being evaluated against those conditions because transportation exposure can influence package integrity over time. Buyers want confidence that packaging performance is consistent throughout expected distribution conditions. Cost is an important part of every procurement decision, although it is no longer viewed in isolation.  A lower-priced material may prove less attractive if qualification demands become more extensive or if future sourcing flexibility becomes limited. Purchasing teams are now weighing immediate savings against the effort required to maintain validated packaging systems over the product lifecycle. Sterile packaging is unlikely to become a standalone purchasing priority detached from device development. Even so, procurement discussions are increasingly based on the understanding that packaging decisions influence manufacturing schedules, quality documentation and commercial readiness. Buyers are treating packaging as a production decision rather than simply a packaging purchase. ...Read more
Packaging validation has become a more visible consideration during medical device manufacturing, even when the package itself has not changed significantly. Companies continue looking at ways to shorten development timelines, yet sterile packaging remains one area where qualification work cannot be compressed without careful planning. The challenge is not limited to selecting an appropriate package design. Each validated packaging process depends on consistent sealing conditions, documented procedures and repeatable manufacturing performance. Small adjustments within production can require additional assessment before devices are released for distribution. Engineering groups often discover that packaging introduces dependencies across several manufacturing functions.  Equipment settings, material handling practices and production documentation all contribute to package consistency. Delays in one area can affect the overall manufacturing schedule, even if the medical device itself is ready for release. Changes during product development add to the complexity.  Device modifications sometimes alter package dimensions or sealing requirements.  Those adjustments may appear minor, although they can trigger additional verification activities before manufacturing resumes under approved conditions. Production teams also face questions about scaling operations.  A packaging process that performs well during limited manufacturing runs may require further evaluation before larger production volumes begin. Consistency becomes increasingly important because package integrity must remain stable across extended manufacturing campaigns rather than isolated batches. Cross-functional coordination receives greater attention under these conditions. Manufacturing engineers, quality personnel and packaging specialists often need to review process changes together instead of treating packaging as a separate production activity. Documentation requirements encourage earlier collaboration because later revisions tend to require additional review. Equipment reliability has entered these discussions as well.  Packaging systems require ongoing monitoring to maintain repeatable sealing performance.  Preventive maintenance and routine verification activities become part of the manufacturing discipline because packaging quality depends on stable equipment conditions throughout production. Manufacturers expanding into additional facilities may encounter further considerations.  Transferring packaging processes between production locations is more than simply relocating equipment. Comparable manufacturing conditions and documented process control become important before equivalent packaging performance can be demonstrated. The result is a gradual shift in how packaging is viewed inside manufacturing organizations. Validation work is increasingly planned alongside production activities rather than after engineering decisions have already been completed. That approach does not necessarily reduce development efforts, although it can stave off interruptions that emerge later in manufacturing. Medical device companies are unlikely to reduce attention on packaging validation as production expectations continue to rise. Buyers, manufacturers and quality teams all have an interest in maintaining package consistency because packaging remains closely connected to product release and distribution readiness. ...Read more
Packaging discussions frequently begin during product development, yet their consequences extend well beyond manufacturing.  Medical device companies are gradually recognizing that sterile packaging influences storage conditions, transportation planning and commercial continuity after products leave the factory. Device developers must consider how packaging supports the intended product throughout distribution.  Transportation conditions, warehouse handling and storage periods all expose packages to different environments before clinical use. Maintaining package integrity in those stages remains an important consideration during package selection. Launch planning can also be affected by packaging readiness.  A device may complete engineering milestones while packaging activities continue through qualification or production preparation.  Those timelines encourage development teams to evaluate packaging earlier because delays near commercial release can affect broader launch schedules. Supply continuity is another practical concern.  Packaging materials are often incorporated into validated manufacturing processes.  Replacing those materials after qualification is rarely a simple purchasing decision because changes may require additional evaluation before production continues under approved procedures. Inventory planning is also becoming more connected to the packaging plan. Manufacturers tend to balance material availability against production schedules while considering the effort required if packaging specifications alter suddenly. Stable sourcing reduces uncertainty for products expected to remain in production over long periods. Global distribution increases the importance of these decisions.  Devices may pass through different shipping routes before reaching hospitals or distributors. Packaging systems must continue protecting sterile barriers in spite of varying transportation conditions and manipulation procedures that occur outside manufacturing facilities. Healthcare providers rarely evaluate packaging from the manufacturer's perspective, yet it is packaging performance that influences product availability.  Delays linked to packaging changes or production interruptions may affect supply planning even when the device design itself remains unchanged.  That possibility encourages manufacturers to consider packaging inside broader business continuity discussions. Commercial planning teams are becoming more involved for similar reasons. Packaging choices can influence inventory transitions, manufacturing flexibility and future product updates. Those conversations go beyond engineering because packaging affects activities that continue long after production begins. However, none of this suggests that sterile packaging has become the dominant factor in medical device commercialization.  Instrument performance remains the primary focus. Even so, packaging decisions increasingly receive attention earlier because they influence multiple stages between manufacturing and product delivery. Medical device companies are treating sterile packaging as part of long-term product management rather than a final production requirement. While packaging may not receive the same visibility as the device itself, its effect reaches across manufacturing, distribution and commercial planning. ...Read more